CLDX
Price
$24.94
Change
-$0.05 (-0.20%)
Updated
Aug 14 closing price
Capitalization
1.66B
82 days until earnings call
ZVRA
Price
$8.90
Change
-$0.53 (-5.62%)
Updated
Aug 14 closing price
Capitalization
490.25M
82 days until earnings call
Interact to see
Advertisement

CLDX vs ZVRA

Header iconCLDX vs ZVRA Comparison
Open Charts CLDX vs ZVRABanner chart's image
Celldex Therapeutics
Price$24.94
Change-$0.05 (-0.20%)
Volume$1.1M
Capitalization1.66B
Zevra Therapeutics
Price$8.90
Change-$0.53 (-5.62%)
Volume$3.39M
Capitalization490.25M
CLDX vs ZVRA Comparison Chart in %
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. ZVRA commentary
Aug 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and ZVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 15, 2025
Stock price -- (CLDX: $24.94 vs. ZVRA: $8.90)
Brand notoriety: CLDX and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 101% vs. ZVRA: 277%
Market capitalization -- CLDX: $1.66B vs. ZVRA: $490.25M
CLDX [@Biotechnology] is valued at $1.66B. ZVRA’s [@Biotechnology] market capitalization is $490.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.07B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, both CLDX and ZVRA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 5 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • CLDX’s TA Score: 5 bullish, 3 bearish.
  • ZVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CLDX is a better buy in the short-term than ZVRA.

Price Growth

CLDX (@Biotechnology) experienced а +17.59% price change this week, while ZVRA (@Biotechnology) price change was -26.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.69%. For the same industry, the average monthly price growth was +27.47%, and the average quarterly price growth was +19.86%.

Reported Earning Dates

CLDX is expected to report earnings on Nov 05, 2025.

ZVRA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+7.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.66B) has a higher market cap than ZVRA($490M). ZVRA YTD gains are higher at: 6.715 vs. CLDX (-1.306). ZVRA has higher annual earnings (EBITDA): -60.3M vs. CLDX (-213.94M). CLDX has more cash in the bank: 673M vs. ZVRA (62.6M). CLDX has less debt than ZVRA: CLDX (3.43M) vs ZVRA (61.8M). ZVRA has higher revenues than CLDX: ZVRA (40.6M) vs CLDX (7.56M).
CLDXZVRACLDX / ZVRA
Capitalization1.66B490M338%
EBITDA-213.94M-60.3M355%
Gain YTD-1.3066.715-19%
P/E RatioN/AN/A-
Revenue7.56M40.6M19%
Total Cash673M62.6M1,075%
Total Debt3.43M61.8M6%
FUNDAMENTALS RATINGS
CLDX vs ZVRA: Fundamental Ratings
CLDX
ZVRA
OUTLOOK RATING
1..100
624
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
7578
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
4958
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
5024

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (62) in the Biotechnology industry is in the same range as ZVRA (80) in the null industry. This means that CLDX’s stock grew similarly to ZVRA’s over the last 12 months.

CLDX's Profit vs Risk Rating (75) in the Biotechnology industry is in the same range as ZVRA (78) in the null industry. This means that CLDX’s stock grew similarly to ZVRA’s over the last 12 months.

CLDX's SMR Rating (95) in the Biotechnology industry is in the same range as ZVRA (100) in the null industry. This means that CLDX’s stock grew similarly to ZVRA’s over the last 12 months.

CLDX's Price Growth Rating (49) in the Biotechnology industry is in the same range as ZVRA (58) in the null industry. This means that CLDX’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (26) in the null industry is significantly better than the same rating for CLDX (100) in the Biotechnology industry. This means that ZVRA’s stock grew significantly faster than CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXZVRA
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 1 day ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 5 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRIRX12.16N/A
N/A
Fidelity Advisor Real Estate Income I
FIJZX54.46N/A
N/A
Fidelity Advisor Consumer Discret Z
LFGSX41.77N/A
N/A
Lord Abbett Focused Growth R4
GOFIX19.24N/A
N/A
GMO Resources III
UIVQX12.99N/A
N/A
MFS Intrinsic Value R4

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-0.20%
BEAM - CLDX
55%
Loosely correlated
+0.63%
RVMD - CLDX
53%
Loosely correlated
-0.14%
DNLI - CLDX
52%
Loosely correlated
-2.36%
CRNX - CLDX
51%
Loosely correlated
-1.33%
IDYA - CLDX
50%
Loosely correlated
-0.20%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with ATXS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
-5.62%
ATXS - ZVRA
34%
Loosely correlated
-1.60%
CLDX - ZVRA
34%
Loosely correlated
-0.20%
MNMD - ZVRA
34%
Loosely correlated
-2.51%
COGT - ZVRA
33%
Loosely correlated
-2.25%
AXON - ZVRA
33%
Loosely correlated
-2.05%
More